Lantheus Share Price Today
(NASDAQ: LNTH)

Name: Lantheus Share Price Today (NASDAQ: LNTH) - Lantheus Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Lantheus share price is $92.51 & ₹8,015.07 as on 1 Feb 2025, 2.30 'hrs' IST

$92.51

▲

-0.28

(-0.3%)

Market is closed - opens 8 PM, 03 Feb 2025

View live Lantheus share price in Dollar and Rupees. Guide to invest in Lantheus stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Lantheus, along with analyst recommendations, forecasts, and comprehensive financials.

Lantheus share price movements

Today's Low: $91.46
Today's High: $95.70
$92.51
1.14%
Downside
Day's Volatility :4.43%
Upside
3.33%
52 Weeks Low: $52.03
52 Weeks High: $126.89
$92.51
43.76%
Downside
52 Weeks Volatility :59.0%
Upside
27.09%

Lantheus (LNTH) Returns

Period	Lantheus Holdings	Sector (Health Care)	Index (Russel 2000)
3 Months	-19.87%	-0.6%	0.0%
6 Months	-6.58%	-2.8%	0.0%
1 Year	71.31%	3.3%	0.0%
3 Years	253.77%	11.6%	-13.7%

Lantheus (LNTH) Key Statistics

in dollars & INR

Previous Close	$92.79
Open	$92.97
Today's High	$95.7
Today's Low	$91.46
Market Capitalization	$6.5B
Today's Volume	$774.5K
52 Week High	$126.8899
52 Week Low	$52.03
Revenue TTM	$1.5B
EBITDA	$548.1M
Earnings Per Share (EPS)	$6.02
PE Ratio	15.41
Profit Margin	28.57%
Quarterly Earnings Growth YOY	-0.05%
Return On Equity TTM	45.53%

How to invest in Lantheus Stock (LNTH) from India?

It is very easy for Indian residents to invest directly in Lantheus from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Lantheus stock in both Indian Rupees (INR) and US Dollars (USD). Search for Lantheus or LNTH on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Lantheus or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Lantheus shares which would translate to 0.009 fractional shares of Lantheus as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Lantheus, in just a few clicks!

Returns in Lantheus (LNTH) for Indian investors in Rupees

The Lantheus stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Lantheus investment value today

Current value as on today

₹1,75,874

Returns

₹75,874

(+75.87%)

Returns from Lantheus Stock

₹71,315 (+71.31%)

Dollar Returns

₹4,559 (+4.56%)

Indian investors sentiment towards Lantheus (LNTH)

17%

Period: Jan 1, 2025 to Jan 31, 2025. Change in 30 Days versus previous period

Search interest for Lantheus Stock from India on INDmoney has increased by 17% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Lantheus

BlackRock Inc
12.28%
Vanguard Group Inc
10.67%
HHG PLC
5.16%
Farallon Capital Management, L.L.C.
4.25%
State Street Corp
3.62%
FMR Inc
3.50%

Analyst Recommendation on Lantheus

Buy

88%Buy

11%Hold

0%Sell

Based on 17 Wall street analysts offering stock ratings for Lantheus(by analysts ranked 0 to 5 stars)

Based on 17 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Lantheus Stock (LNTH)

What analysts predicted

Upside of 45.6%

Target:

$134.69

Current:

$92.51

Insights on Lantheus Stock (Ticker Symbol: LNTH)

Price Movement
In the last 1 year, LNTH stock has moved up by 74.5%
Decreasing Revenue
Revenue is down for the last 2 quarters, 394.09M → 378.73M (in $), with an average decrease of 3.9% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, 62.07M → 131.09M (in $), with an average increase of 52.7% per quarter
LNTH vs ITCI (1 yr)
In the last 1 year, Intra-cellular Therapies, Inc. has given 86.4% return, outperforming this stock by 11.9%
Price to Sales
ForLNTH every $1 of sales, investors are willing to pay $4.3, whereas for Intra-cellular Therapies, Inc., the investors are paying $20.8 for every $1 of sales.

LNTH Lantheus Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$343.4M	↑ 3.62%
Net Income	$40.5M	↓ 67.16%
Net Profit Margin	11.8%	↓ 25.43%

	FY19	Y/Y Change
Revenue	$347.3M	↑ 1.15%
Net Income	$31.7M	↓ 21.84%
Net Profit Margin	9.12%	↓ 2.68%

	FY20	Y/Y Change
Revenue	$339.4M	↓ 2.28%
Net Income	$-13.5M	↓ 142.55%
Net Profit Margin	-3.97%	↓ 13.09%

	FY21	Y/Y Change
Revenue	$425.2M	↑ 25.28%
Net Income	$-71.3M	↑ 429.05%
Net Profit Margin	-16.76%	↓ 12.79%

	FY22	Y/Y Change
Revenue	$935.1M	↑ 119.91%
Net Income	$28.1M	↓ 139.38%
Net Profit Margin	3.0%	↑ 19.76%

	FY23	Y/Y Change
Revenue	$1.3B	↑ 38.65%
Net Income	$326.7M	↑ 1063.86%
Net Profit Margin	25.2%	↑ 22.2%

	Q2 FY23	Q/Q Change
Revenue	$321.7M	↑ 6.95%
Net Income	$94.1M	↓ 3453.44%
Net Profit Margin	29.26%	↑ 30.19%

	Q3 FY23	Q/Q Change
Revenue	$319.9M	↓ 0.55%
Net Income	$132.0M	↑ 40.18%
Net Profit Margin	41.24%	↑ 11.98%

	Q4 FY23	Q/Q Change
Revenue	$354.0M	↑ 10.64%
Net Income	$103.4M	↓ 21.66%
Net Profit Margin	29.2%	↓ 12.04%

	Q1 FY24	Q/Q Change
Revenue	$370.0M	↑ 4.51%
Net Income	$131.1M	↑ 26.78%
Net Profit Margin	35.43%	↑ 6.23%

	Q2 FY24	Q/Q Change
Revenue	$394.1M	↑ 6.52%
Net Income	$62.1M	↓ 52.64%
Net Profit Margin	15.75%	↓ 19.68%

	Q3 FY24	Q/Q Change
Revenue	$378.7M	↓ 3.9%
Net Income	$131.1M	↑ 111.19%
Net Profit Margin	34.61%	↑ 18.86%

	FY18	Y/Y Change
Profit	$174.9M	↑ 7.86%

	FY19	Y/Y Change
Profit	$174.8M	↓ 0.04%

	FY20	Y/Y Change
Profit	$138.8M	↓ 20.62%

	FY21	Y/Y Change
Profit	$187.7M	↑ 35.26%

	FY22	Y/Y Change
Profit	$581.7M	↑ 209.92%

	FY23	Y/Y Change
Profit	$709.5M	↑ 21.98%

	Q2 FY23	Q/Q Change
Profit	$202.6M	↑ 162.92%

	Q3 FY23	Q/Q Change
Profit	$200.0M	↓ 1.33%

	Q4 FY23	Q/Q Change
Profit	$229.9M	↑ 14.96%

	Q1 FY24	Q/Q Change
Profit	$251.8M	↑ 9.53%

	Q2 FY24	Q/Q Change
Profit	$255.8M	↑ 1.59%

	Q3 FY24	Q/Q Change
Profit	$242.1M	↓ 5.34%

	FY18	Y/Y Change
Operating Cash Flow	$61.2M	↑ 11.71%
Investing Cash Flow	$-19.1M	↑ 17.31%
Financing Cash Flow	$-4.7M	↓ 65.29%

	FY19	Y/Y Change
Operating Cash Flow	$80.4M	↑ 31.36%
Investing Cash Flow	$-22.1M	↑ 15.31%
Financing Cash Flow	$-78.9M	↑ 1589.82%

	FY20	Y/Y Change
Operating Cash Flow	$16.4M	↓ 79.6%
Investing Cash Flow	$-4.9M	↓ 77.73%
Financing Cash Flow	$-21.9M	↓ 72.29%

	FY21	Y/Y Change
Operating Cash Flow	$53.9M	↑ 228.84%
Investing Cash Flow	$3.7M	↓ 174.98%
Financing Cash Flow	$-39.3M	↑ 79.92%

	FY22	Y/Y Change
Operating Cash Flow	$281.8M	↑ 422.63%
Investing Cash Flow	$-276.5M	↓ 7608.74%
Financing Cash Flow	$311.7M	↓ 892.46%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-32.3M	↓ 129.74%
Investing Cash Flow	$-20.7M	↓ 53.5%
Financing Cash Flow	$-4.1M	↓ 53.27%

Lantheus Technicals Summary

Sell

Neutral

Buy

Lantheus is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Lantheus (LNTH) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Lantheus Holdings	4.18%	-6.58%	71.31%	253.77%	276.21%
Intra-cellular Therapies, Inc.	50.85%	63.34%	88.97%	164.42%	462.3%
Haleon Plc Spon Ads	0.32%	-0.42%	13.96%	27.8%	27.8%
Zoetis Inc.	5.1%	-2.24%	-9.6%	-15.47%	26.11%
Neurocrine Biosciences Inc.	10.13%	2.79%	7.11%	92.79%	51.14%
Viatris Inc.	-9.18%	-2.42%	-4.81%	-26.27%	-30.97%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Lantheus Holdings	15.41	15.41	0.61	6.75	0.46	0.17	NA	16.97
Intra-cellular Therapies, Inc.	NA	NA	0.0	-0.7	-0.1	-0.07	NA	10.8
Haleon Plc Spon Ads	29.0	29.0	1.7	0.36	0.07	0.04	0.02	1.82
Zoetis Inc.	32.12	32.12	2.69	5.89	0.47	0.15	0.01	11.59
Neurocrine Biosciences Inc.	40.38	40.38	0.35	6.59	0.16	0.12	NA	26.87
Viatris Inc.	224.4	NA	0.07	2.68	-0.04	0.02	0.04	16.58

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Lantheus Holdings	Buy	$6.5B	276.21%	15.41	28.57%
Intra-cellular Therapies, Inc.	Buy	$13.5B	462.3%	NA	-14.07%
Haleon Plc Spon Ads	Buy	$43.3B	27.8%	29.0	10.75%
Zoetis Inc.	Buy	$77.1B	26.11%	32.12	26.55%
Neurocrine Biosciences Inc.	Buy	$15.4B	51.14%	40.38	17.21%
Viatris Inc.	Hold	$13.5B	-30.97%	224.4	-5.87%

About Lantheus

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Organization	Lantheus
Employees	834
CEO	Mr. Brian A. Markison
Industry	Health Technology

Management People of Lantheus

Name	Title
Mr. Brian A. Markison	CEO & Director
Mr. Paul M. Blanchfield	President
Mr. Robert J. Marshall Jr., CFA	CFO & Treasurer
Dr. Jean-Claude Provost M.D.	Chief Science Officer
Mr. Daniel M. Niedzwiecki	Chief Administrative Officer, General Counsel & Corporate Secretary
Ms. Kimberly Brown	Chief Accounting Officer
Ms. Dorothy Barr	Senior Vice President of Manufacturing & Technical Operations
Ms. Lee Anne Howe	Chief Information Officer
Mr. Mark Richard Kinarney	Senior Director of Investor Relations
Ms. Linda S. Lennox	VP of Corporate Communications & Chief of Staff

Important FAQs about investing in LNTH Stock from India :

What is Lantheus share price today?

Lantheus share price today stands at $92.51, Open: $92.97 ; Previous Close: $92.79 ; High: $95.70 ; Low: $91.46 ; 52 Week High: $126.89 ; 52 Week Low: $52.03.

The stock opens at $92.97, after a previous close of $92.79. The stock reached a daily high of $95.70 and a low of $91.46, with a 52-week high of $126.89 and a 52-week low of $52.03.

Can Indians buy Lantheus shares?

Yes, Indians can invest in the Lantheus (LNTH) from India.

With INDmoney, you can buy Lantheus at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Lantheus at zero transaction cost.

How can I buy Lantheus shares from India?

It is very easy to buy Lantheus from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Lantheus (LNTH) be purchased?

Yes, you can buy fractional shares of Lantheus with INDmoney app.

What are the documents required to start investing in Lantheus stocks?

To start investing in Lantheus, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.